Becton, Dickinson and Co. | BDX - Current Assets


Becton, Dickinson and Co. reported $8.01B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Agilent USD 4.76B 148M Mar/2026
Align Technology USD 2.66B 38.87M Mar/2026
AngioDynamics USD 161.35M 4.69M Sep/2025
Avanos Medical USD 325M 30.4M Mar/2026
Baxter International USD 6.85B 25M Mar/2026
Becton, Dickinson and Co. USD 8.01B 1.18B Mar/2026
Bio-Rad Laboratories USD 2.94B 35.9M Mar/2026
Boston Scientific USD 8.68B 110M Mar/2026
Cooper Companies USD 2.3B 166M Mar/2026
Danaher USD 13.94B 1.18B Mar/2026
Dentsply International USD 1.85B 178M Mar/2026
Dexcom USD 4.33B 298.4M Mar/2026
Edwards Lifesciences USD 6.23B 510.2M Mar/2026
Globus Medical USD 2.2B 72.51M Mar/2026
Insulet USD 1.71B 204.5M Mar/2026
Integra LifeSciences USD 1.17B 12.47M Mar/2026
Intuitive Surgical USD 11.52B 881.5M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Medtronic USD 24.07B 75M Dec/2025
Solventum Corp USD 3.58B 276M Mar/2026
Stryker USD 13.34B 1.42B Mar/2026
Tandem Diabetes Care USD 887.1M 268.96M Mar/2026
Teleflex USD 1.86B 78.67M Mar/2026
Terumo JPY 861.04B 45.48B Mar/2026
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Zimmer Biomet Holdings USD 4.96B 157.4M Mar/2026